Eric Raymond

Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).

E. Van Cutsem, E. Raymond, A. Vinik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study.

M. J. van den Bent, D. Lacombe, E. Raymond, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC).

M. Mariani, S. Tagawa, J. Bleuse, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.